Physician profile
Marta I Blesa
NPI 1881614378
$1,739.46
in general payments reported to CMS, 2019-2025
15 companies · $55.82 in 2025
The $55.82 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $251 · 2021: $580 · 2022: $543 · 2023: $120 · 2024: $50.51 · 2025: $55.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $226.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $600.70 | 2020-2022 | |
| Novo Nordisk INC | $392.19 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $137.74 | 2019-2020 | |
| Abbvie INC. | $135.27 | 2020-2021 | |
| Amarin Pharma, INC. | $125.29 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.38 | 2021-2023 | |
| Dexcom, INC. | $45.47 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $40.74 | 2023-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Astrazeneca Pharmaceuticals LP | $35.15 | 2020 | |
| Cranial Technologies, INC | $34.69 | 2022-2025 | Doc Band |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.89 | 2023 | Xifaxan, Trulance |
| Pfizer INC. | $23.80 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.78 | 2021 | |
| Lilly USA, LLC | $20.74 | 2019 | |
| Allergan, INC. | $16.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marta Blesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.